7YAW image
Entry Detail
PDB ID:
7YAW
Title:
Crystal structure of ZAK in complex with compound YH-180
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-06-28
Release Date:
2023-08-09
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Mitogen-activated protein kinase kinase kinase MLT
Chain IDs:A (auth: D), B (auth: A), C (auth: B), D (auth: C)
Chain Length:310
Number of Molecules:4
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov).
J.Med.Chem. 66 7405 7420 (2023)
PMID: 37220641 DOI: 10.1021/acs.jmedchem.3c00088

Abstact

Covalent kinase inhibitors (CKIs) hold great promise for drug development. However, examples of computationally guided design of CKIs are still scarce. Here, we present an integrated computational workflow (Kin-Cov) for rational design of CKIs. The design of the first covalent leucine-zipper and sterile-α motif kinase (ZAK) inhibitor was presented as an example to showcase the power of computational workflow for CKI design. The two representative compounds, 7 and 8, inhibited ZAK kinase with half-maximal inhibitory concentration (IC50) values of 9.1 and 11.5 nM, respectively. Compound 8 displayed an excellent ZAK target specificity in Kinome profiling against 378 wild-type kinases. Structural biology and cell-based Western blot washout assays validated the irreversible binding characteristics of the compounds. Our study presents a rational approach for the design of CKIs based on the reactivity and accessibility of nucleophilic amino acid residues in a kinase. The workflow is generalizable and can be applied to facilitate CKI-based drug design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures